Oral guanfacine treatment ameliorates the ADHD-like symptoms caused by developmental manganese exposure.

Ellie Fisher, Stephane A Beaudin, Barbara J Strupp, Donald R Smith

Abstract read

In one paragraph

Article in Progress in neuro-psychopharmacology & biological psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ellie FisherDepartment of Microbiology and Environmental Toxicology, University of California, Santa Cruz, CA, USA.

Stephane A BeaudinDepartment of Microbiology and Environmental Toxicology, University of California, Santa Cruz, CA, USA.

Barbara J StruppDivision of Nutritional Sciences and Department of Psychology, Cornell University, Ithaca, NY, USA.

Donald R SmithDepartment of Microbiology and Environmental Toxicology, University of California, Santa Cruz, CA, USA.

Funding

Mechanisms and therapies for the neurobehavioral deficits from early Mn exposureR01ES028369 · NIEHS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SMITH, DONALD R · 2018 to 2023

$2.8M

NIEHS NIH HHS R01 ES028369

6 · The paper itself

Abstract

Epidemiological studies have linked developmental manganese (Mn) exposure to increased risk of ADHD and related symptoms in children and adolescents. Rodent model studies have 1) confirmed causality by demonstrating that developmental Mn exposure can cause lasting ADHD-like symptoms, 2) revealed that these symptoms (in Mn-exposed animals) are accompanied by a hypofunctioning catecholaminergic system in fronto-cortical-striatal brain areas, and 3) demonstrated that methylphenidate is efficacious in ameliorating these ADHD-like symptoms in Mn-exposed animals. However, stimulant medications such as methylphenidate do not lessen symptoms in 25-30 % of children and adolescents diagnosed with ADHD, indicating the need for alternative ADHD medications. Guanfacine, a specific noradrenergic α

Indexed as

Adrenergic alpha-2 Receptor AgonistsAttention Deficit Disorder with HyperactivityGuanfacineManganeseAdministration, OralAnimalsDisease Models, AnimalMaleRatsAdrenergic alpha-2 Receptor AgonistsGuanfacineManganeseAttentionAttention deficit hyperactivity disorderEnvironmental exposureImpulse controlInfant developmentManganeseSensorimotor skills

Identifiers

PMID41057091

DOI10.1016/j.pnpbp.2025.111517

PMCPMC13333142

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.